Premium
ANTIGENICITY AND EFFICACY OF AUTHENTIC SEQUENCE RECOMBINANT HUMAN GROWTH HORMONE (SOMATROPIN): FIRST‐YEAR EXPERIENCE IN THE UNITED KINGDOM
Author(s) -
BUZI F.,
BUCHANAN C. R.,
MORRELL D. J.,
PREECE M. A.
Publication year - 1989
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.1989.tb01425.x
Subject(s) - somatropin , immunogenicity , endocrinology , medicine , antigenicity , growth hormone deficiency , recombinant dna , somatomedin , antibody , growth hormone , human growth hormone , hormone , biology , immunology , biochemistry , gene
SUMMARY Twenty‐one children were treated for GH deficiency with authentic sequence biosynthetic human GH (somatropin), 60 μg/kg body weight, subcutaneously, three times weekly for 1 year or longer. The magnitude of growth response and rise in serum insulin‐like growth factor I levels were similar to those expected from experience with pituitary GH and somatrem. Three patients developed serum antibodies to GH with a binding capacity < 0.02 μg/l, but in only one patient was the GH binding capacity < 10 μg/l and he showed no attenuation of growth response. Eschericliia coli polypeptide antibodies did not rise significantly and no clinically important side‐effects occurred. Somatropin is safe, effective and of low immunogenicity in the treatment of GH deficiency.